Session » Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease

Date: Monday, October 22, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1785

A Data-Driven Approach to Guide Physicians When Considering the Differential Diagnosis of IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1800

A Declining Trend in Frequency of Secondary Amyloidosis in Behçet’s Syndrome

9:00AM-11:00AM: Abstract Number: 1790

An Unmet Need for Oral Ulcer Activity in Patients with Behcet’s Disease: A Multi-National Study

9:00AM-11:00AM: Abstract Number: 1797

An Update on Pulmonary Artery Involvement in Behcet’s Syndrome: More Pulmonary Artery Thrombotic Disease and a Better Outcome

9:00AM-11:00AM: Abstract Number: 1815

Aneurysmal Lesions in Behcet’s Disease: A Report of 69 Cases from a Single Center

9:00AM-11:00AM: Abstract Number: 1772

Apremilast in Refractory Oral and/or Genital Ulcers in Behçet’s Disease. Multicenter Study of 37 Cases

9:00AM-11:00AM: Abstract Number: 1803

Assessment of Severity and Risk Factors of Post-Thrombotic Syndrome in Vascular Behçet Disease: Muticentered Retrospective Study

9:00AM-11:00AM: Abstract Number: 1802

Behcet’s Disease in the Southwestern United States

9:00AM-11:00AM: Abstract Number: 1812

Characterization and Prevalence of Morbus Behçet in Switzerland

9:00AM-11:00AM: Abstract Number: 1782

Cigarette Smoking Is a Risk Factor for IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1809

Clinical Characteristics of Older Age-Onset Behçet Syndrome Patients

9:00AM-11:00AM: Abstract Number: 1807

Clinical Features and Disease Course of Neurologic Involvement in Behcet’s Disease

9:00AM-11:00AM: Abstract Number: 1776

Clinical Significance of Allergy in IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1773

Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis Due to Behçet’s Disease. National Multicenter Study of 177 Cases

9:00AM-11:00AM: Abstract Number: 1778

Comparison of Clinical and Angiographic Features of Arterial Involvement in Takayasu’s Arteritis and Behcet’s Disease

9:00AM-11:00AM: Abstract Number: 1811

Efficacy and Safety of Interferon α2a As an Add-on Treatment for Refractory Behcet’s Uveitis

9:00AM-11:00AM: Abstract Number: 1791

Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome in a Phase III Study: A Prespecified Analysis By Baseline Patient Demographics and Disease Characteristics

9:00AM-11:00AM: Abstract Number: 1801

Factors Associated with Damage Progression in Behçet’s Syndrome Uveitis

9:00AM-11:00AM: Abstract Number: 1777

Factors Related to Deterioration of IgG4-Related Disease in Untreated Patients with IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1786

Favourable Response to Rituximab for the Treatment of IgG4-Related Disease: Long-Term Follow-up of 10 Patients Resistant to Glucocorticoids and Immunosuppressives

9:00AM-11:00AM: Abstract Number: 1787

How to Better Diagnose IgG4 Related Disease: a Single-Center Based Experience

9:00AM-11:00AM: Abstract Number: 1775

IgG4-Related Disease, Clinical Series on Chilean Patients

9:00AM-11:00AM: Abstract Number: 1808

Increased Frequency of Obstructive Sleep Apnea Syndrome in Behcet’s Syndrome Patients with Vena Cava Superior Thrombosis

9:00AM-11:00AM: Abstract Number: 1799

Increased Vein Wall Thickness in Behçet’s Syndrome

9:00AM-11:00AM: Abstract Number: 1810

Initial Visit Symptoms in Probable Behçet’s Predictive of ISG Criteria Behçet’s: Data from New York and Amsterdam Cohorts

9:00AM-11:00AM: Abstract Number: 1814

Interferon-Alpha for the Management of Lower Extremity Deep Vein Thrombosis in Behcet’s Syndrome: A Case Series

9:00AM-11:00AM: Abstract Number: 1779

Is the Number of IgG4+ Plasma Cells Observed By Immunostaining Important Beyond Its Diagnostic Utility in IgG4-Related Disease?

9:00AM-11:00AM: Abstract Number: 1798

Leg Ulcers in Behçet’s Syndrome: An Observational Survey in 24 Patients

9:00AM-11:00AM: Abstract Number: 1789

Mucocutaneous Activity Index As a Patient-Reported Outcome Measure in Behcet’s Disease: A Multi-Center Study from Turkey

9:00AM-11:00AM: Abstract Number: 1795

New Major Organ Involvement Is Lower in Young Male Behçet’s Patients Compared to Retrospective Series: Five-Year Results of a Prospective Cohort

9:00AM-11:00AM: Abstract Number: 1813

Non-Aphthous Beginning As an Independent Risk Factor for the Course of Behçet’s Disease

9:00AM-11:00AM: Abstract Number: 1804

Optimization Protocol for Adalimumab Treatment in Refractory Uveitis Due to Behçet’s Disease

9:00AM-11:00AM: Abstract Number: 1788

Predictive Factors for Work-Day Loss in a Multi-Center Study in Behcet’s Disease: Indirect Costs for Healthcare

9:00AM-11:00AM: Abstract Number: 1781

Retrospective Analysis of IgG4-RD Patient Population at the Cleveland Clinic between 2007-2017

9:00AM-11:00AM: Abstract Number: 1796

Retrospective Analysis of Initial Presentation Findings of Behcet’s Syndrome throughout 4 Decades

9:00AM-11:00AM: Abstract Number: 1783

Salivary Gland Disease in IgG4-Related Disease Is Associated with Allergic Histories

9:00AM-11:00AM: Abstract Number: 1784

Serum IgG4 Test Characteristics: Immunonephelometry Versus Liquid Chromatography Tandem Mass Spectrometry

9:00AM-11:00AM: Abstract Number: 1780

Shear Wave Elastography in the Evaluation of Submandibular Gland Characteristics in IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1806

Spinal Cord Involvement in Behcet’s Disease- Experience of a Vasculitis Centre at Silk Road

9:00AM-11:00AM: Abstract Number: 1805

Strong Association of HLA-DRB1*0901 with Japanese Patients with Chronic Progressive Neuro-Behçet’s Disease

9:00AM-11:00AM: Abstract Number: 1793

The Omeract Core Domain Set for Clinical Trials in Behçet’s Syndrome

9:00AM-11:00AM: Abstract Number: 1774

The Relationship between Serum Cholinesterase, Dickkopf-1 and Number of Organ Involvement in Japanese Patients with IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1794

Venous Vessel Wall Thickness in Lower Extremity Is Increased in Male Behcet’s Disease Patients

9:00AM-11:00AM: Abstract Number: 1792

Work Productivity Is Impaired in Patients with Behcet’s Syndrome

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].